

Screening of Helicobacter Pylori Infection in Patients with Telogen Effluvium

Sherine H. Abd El Rahman, Eman A. El hady, Karem T. Khalil

Dermatology, Venereology and
Andrology Department, Faculty
of Medicine Benha University,
Egypt.

Corresponding to:

Dr. Karem T. Khalil.

Dermatology, Venereology and
Andrology Department, Faculty of
Medicine Benha University, Egypt.

Email:

Karem.khalil@fmed.bu.edu.eg

Received: 11 March 2024

Accepted: 3 April 2024

Abstract:

Background: Background: Telogen effluvium (TE) is a scalp condition characterized by hair shedding that is diffuse and does not leave scars. Helicobacter pylorus (H. pylori) is a microaerophilic gram-negative bacterium that colonizes the gastric mucosa and is found in around 50% of the global population. **Aim:** To screen for the presence of H. pylori in patients with TE. **Methods:** The study comprised 50 female patients with TE and 30 apparently healthy age-matched females as controls. Laboratory tests were performed, including a complete blood count, serum ferritin, and stool analysis for H. pylori Ag. **Results:** Hemoglobin (Hb), hematocrit (HCT), serum ferritin levels were significantly lower in cases compared to controls ($p=0.002$, <0.001 , <0.001 , respectively). The mean level of Hb and HCT differed substantially between categories of TE severity ($p = 0.008$, 0.009 , respectively). H. pylori was detected with statistical significance in cases compared to controls ($p<0.001$). Serum ferritin, Hb and HCT levels were substantially lower in individuals with positive H. pylori Ag than those with negative H. pylori Ag ($p=0.02$, 0.004 , 0.004 , respectively). Serum ferritin levels less than 75.5 ng/ml can be used as a cutoff point to predict the development of TE ($p<0.001$). **Conclusion:** H. pylori should be tested in TE patients, particularly those with iron insufficiency.

Keywords: Helicobacter pylori; Hair loss; Ferritin; Telogen Effluvium.

Introduction

The loss of hair is a widespread disorder with many different manifestations. Telogen effluvium (TE) is a scalp condition that causes diffuse, non-scarring hair loss. Several hypotheses were proposed addressing the pathophysiology of TE. It is believed that several functional types of TE exist based on changes throughout specific stages of the follicular cycle. TE has been linked to a variety of insults, including physical, mental, and chemical ⁽¹⁾.

Acute TE is characterized by hair loss that occurs three months following the triggering incident ⁽²⁾. However, chronic TE can be defined as idiopathic, extensive falling of telogen hairs from the scalp for more than six months ⁽³⁾. The hair thickness seems normal, with shorter regrowing hairs, and hair pull examination is typically helpful in diagnosis ⁽⁴⁾. Many studies looked into the association between iron deficiency and hair loss. The majority of them targeted women, and several claimed that iron deficiency, even in the absence of anemia, might cause TE ⁽⁵⁾.

Iron insufficiency is frequent among women who experience hair loss ⁽⁶⁾. Nonetheless, the link between hair loss and low serum ferritin levels has been contested for years. There is ongoing debate over whether low serum ferritin levels should be classified as a dietary deficiency causing hair loss (mostly TE) ⁽⁷⁾. Menstruation is the leading cause of iron deficiency among otherwise healthy premenopausal women. Hemoglobin and ferritin reference ranges for women of reproductive age are frequently reported to be lower than those for men of the same age ⁽⁸⁾.

Helicobacter pylori (*H. pylori*) are a microaerophilic gram-negative bacterium that colonizes the stomach mucosa and is found in around 50% of the global population. The prevalence of *H. pylori* infection is 60.9% in children under the age of 12 and 77.2% in adults ⁽⁹⁾.

Infection with *H. pylori* has been linked to gastrointestinal disorders such as active chronic gastritis, peptic ulcers, and gastric cancer ⁽¹⁰⁾. It has also been linked to extra-gastric symptoms such as thrombocytopenic purpura, reduced growth velocity, and iron shortage and/or anemia ⁽¹¹⁾. Some investigations have found that by eliminating *H. pylori* bacteria, indices of iron nutritional status recover to normal levels, eliminating the need for iron supplementation ⁽¹²⁾.

The goal of this study was to screen for the presence of *H. pylori* infection in TE patients.

Patients and methods

The present study was a cross-sectional case-control research. Fifty female patients with TE were included. In addition, 30 apparently healthy, age-matched volunteer females served as the control group. The study took place in the Dermatology, Andrology, and Venereology Department of Benha University Hospitals from October 2021 to January 2023.

Female patients over the age of 18 who suffered from hair loss and met the TE criteria were enrolled. However, patients older than 18 years old, receiving drugs that cause hair fall, such as antikeratinizing, anticoagulant, antithyroid, anticonvulsant, and hormones were excluded from the study. Other types of hair loss, such as alopecia areata, traction alopecia, or female pattern hair loss; patients under treatment for *H. pylori*; history of polycystic ovary or menstrual irregularities; postmenopausal or pregnant women; acute inflammatory conditions or infections; and chronic liver, renal, heart, or autoimmune diseases, were not eligible to share in the study.

Ethical considerations:

The study was carried out following approval by the Research Ethics Committee of Benha Faculty of Medicine, Benha University (MS.27.9.2021). Each subject provided informed written consent.

Each participant was given a secret code number and an explanation of the study's objective.

Methodology:

All participants were asked to provide a comprehensive background, including their age, length of hair loss, drug use, and chronic systemic illnesses. In addition, a general examination was performed, with body mass index (BMI) estimated as weight (kilogram) / height (square meter).

Dermatologic examination was performed, with the patients seated on a chair rather than an examination table for better visualization. The entire scalp (back, front, top, and sides) was checked under good illumination.

The hair pull test was used to assess the severity of TE⁽¹³⁾. The procedure involved picking 50 to 60 hairs and holding the bundle close to the scalp between the thumb, index finger, and middle finger before firmly tugging the bundle with slow traction as the fingers travelled down the hair shaft. It was done on the vertex, two parietal areas, and the occipital region of the scalp.

Next, pulled hairs were counted. When > 10% of the hairs in each bundle are pulled from a scalp location, the hair pull test is positive. If < 10% of the hair is gone, the loss is probably caused by natural shedding. The current study used three levels of severity for the pull test: mild if it is positive in one scalp location, moderate if it is positive in two areas and severe if it is positive in more than two.

Trichoscopy was also performed using a manual dermoscope, DermLite 4 (DL4) (3Gen Inc., USA), to confirm the diagnosis. TE was distinguished by observations such as decreased hair density in the presence of empty follicles. On the other hand, female-pattern hair loss is characterized by follicular miniaturization.

A complete blood count, serum ferritin measurement, and *H. pylori* stool antigen test (HpSAg) were all conducted in the

laboratory. The enzyme-linked immunosorbent assay (ELISA) (KaiBiLi *H. Pylori* Antigen Rapid Test) was used to detect HpSAg. To rule out individuals with inflammatory disorders, C-reactive protein levels were measured before the study began.

Statistical analysis

The data was analyzed using IBM SPSS v26 (IBM Corp., Armonk, New York, USA). Descriptive statistical methods for numerical data included mean and standard deviation, while frequency and percentage were employed for non-numerical data. The student's t-test was used to determine significance for parametric data, whereas the Mann-Whitney U-test was employed for non-parametric data. Multiple groups were compared using ANOVA and Kruskal-Wallis tests. To compare categorical data, the chi square test (X²-value) was applied. A ROC curve analysis was performed to determine the optimum cutoff point and indicative power of the test. P-values < 0.05 imply statistical significance.

Results

The mean serum ferritin, hemoglobin (Hb), and hematocrit (HCT) levels were considerably lower in patients than controls. *H. pylori* Ag was positive in 60%, 20% of patients, and controls, respectively ($p < 0.001$) (Table 1).

In terms of TE severity, the current study found that patients were classified as moderate (62%), severe (26%), or mild (12%) based on the pull test (Table 1).

There were statistically significant differences in Hb and HCT levels among different grades of TE, with the lowest levels in severe cases ($p = 0.008, 0.009$, respectively). However, no significant change was found in serum ferritin ($p = 0.6$) (Table 2).

Serum ferritin, Hb, and HCT levels were significantly lower in those with positive *H. pylori* Ag versus those with negative *H. pylori* Ag (Table 3).

According to existing data, a serum ferritin level of less than 75.5 ng/mL can indicate

TE with 75% specificity and 80% sensitivity (Table 4, Figure 1).

Table 1: Comparison between studied groups regarding clinical and laboratory findings.

| Characteristics | Case (n=50) | | Control (n=30) | | t | P |
|---|-------------|----------|----------------|----------|----------------------|----------|
| | Mean | ± SD | Mean | ± SD | | |
| Age (Year) | 26.60 | 6.34 | 25.20 | 4.89 | 1.1 | 0.3 |
| Age range | 18-42 | | 18-34 | | | |
| BMI (kg/m ²) | 23.76 | 3.22 | 22.50 | 2.24 | 1.9 | 0.06 |
| RBCs (N=3.5-5 million/µl) | 4.41 | 0.30 | 4.47 | 0.30 | 0.9 | 0.4 |
| Hb (N=11.5–15 g/dl) | 11.22 | 1.01 | 11.83 | 0.64 | 3.3 | 0.002* |
| HCT (N=34-44 %) | 35.33 | 2.82 | 37.48 | 2.11 | 3.9 | <0.001* |
| MCH (N=26–34 pg) | 25.76 | 2.22 | 26.39 | 1.80 | 1.3 | 0.2 |
| MCV (N=73 – 98 fl) | 80.30 | 5.74 | 82.32 | 5.59 | 1.5 | 0.1 |
| WBCs (N=4–11 10 ³ /µl) | 7.44 | 2.32 | 7.25 | 1.88 | 0.4 | 0.7 |
| Platelets (N=150–450 10 ³ /µl) | 296.86 | 68.94 | 316.87 | 95.16 | 1.1 | 0.3 |
| Serum ferritin(N=6-150 ng/ml) | 41.22 | 29.49 | 75.40 | 22.97 | 5.8 | <0.001* |
| H. pylori Ag | No. | % | No. | % | X² | P |
| Negative | 20 | 40 | 24 | 80 | 12.1 | <0.001* |
| Positive | 30 | 60 | 6 | 20 | | |
| TE severity | No. | % | | | | |
| Mild | 6 | 12 | | | | |
| Moderate | 31 | 62 | | | | |
| Severe | 13 | 26 | | | | |

BMI = Body mass index; RBCs = Red blood cells; Hb= Haemoglobin; HCT=Hematocrit; MCH= mean corpuscular Haemoglobin; MCV= Mean corpuscular volume; WBCs = White blood cells; TE= Telogen effluvium; H. pylori Ag = Helicobacter pylori antigen; t= student t test; SD= standard deviation; X²=Chi square test; *significant <0.05.

Table 2: Serum ferritin, Hb, and HCT levels in relation to TE severity.

| | | n | Mean | ± SD | Test of significance | P |
|--|----------|----|---------|-------|----------------------|--------|
| Serum ferritin (N=6-159 ng/ml) | Mild | 6 | 52.00 | 22.27 | z =0.5 | 0.6 |
| | Moderate | 31 | 39.26 | 29.41 | | |
| | Severe | 13 | 40.92 | 33.39 | | |
| Hb (N=11.5–15 g/dl) | Mild | 6 | 12.1333 | 0.99 | f = 5.27 | 0.008* |
| | Moderate | 31 | 11.2839 | 0.98 | | |
| | Severe | 13 | 10.6615 | 0.77 | | |
| HCT (N=34-44 %) | Mild | 6 | 37.8333 | 2.42 | f =5.16 | 0.009* |
| | Moderate | 31 | 35.5194 | 2.76 | | |
| | Severe | 13 | 33.7769 | 2.28 | | |

Hb= Haemoglobin; HCT=Hematocrit; z =Kruskal Wallis test; f=Anova test; SD= standard deviation; *significant <0.05.

Table 3: Serum ferritin, Hb and HCT in relation to H. Pylori Ag.

| Characteristics | Negative H. Pylori (n=44) | | Positive H. Pylori (n=36) | | Test of significance | P |
|--|------------------------------|-------|------------------------------|-------|-------------------------|--------|
| | Mean | SD | Mean | SD | | |
| Serum ferritin (N=6 -159 ng/ml) | 61.68 | 31.56 | 44.69 | 29.89 | U=2.5 | 0.02* |
| Hb (N=11.5–15 g/dl) | 11.7 | 0.86 | 11.1 | 0.90 | t = 2.9 | 0.004* |
| HCT (N=34-44 %) | 36.93 | 2.56 | 35.16 | 2.73 | t=2.9 | 0.004* |

Hb= Hemoglobin; HCT=Hematocrit; H. pylori Ag = Helicobacter pylori antigen; U=Mann Whitney U test; t= student t test; SD= standard deviation; *significant <0.05.

Table 4: Receiver Operating Characteristic (ROC) curve analysis of the cutoff values of serum ferritin for prediction of TE.

| Variable | Cutoff value | AUC | 95% CI | Sensitivity | Specificity | P |
|--------------------------------|--------------|------|-------------|-------------|-------------|---------|
| Serum ferritin (N=6-159 ng/ml) | <75.5 | 0.81 | 0.72 - 0.91 | 80 | 75 | <0.001* |

AUC= Area under the Curve; *significant <0.05.




Figure 1: ROC curve analysis of the cutoff values of serum ferritin for prediction of TE

Discussion

Telogen effluvium (TE) is a result of a disruption in the normal growth cycle of hair that occurs for a variety of reasons. It was hypothesized that regardless of the source of hair loss, the follicle tends to exhibit premature anagen termination. Afterwards, the follicle enters catagen and rests, simulating telogen⁽¹⁴⁾.

Iron is involved in DNA synthesis. In the bulge area, gene expression is iron-regulated^(7, 15). The reduced ferritin level in TE patients could be attributed to a variety of causes⁽¹⁶⁾. Several investigations reported blood ferritin concentrations ranging from 15 to 70 ng/ml in cases of iron insufficiency⁽¹⁷⁾. To restore severe TE-related hair loss, several publications advocated keeping ferritin levels > 40ng/ml⁽¹⁸⁾ or 70ng/ml⁽¹⁹⁾.

Some studies have identified reduced serum iron in TE patients, whereas others have found no link. The association between serum ferritin and hair loss is a contentious issue⁽²⁰⁾.

In the current study, patients showed considerably lower levels of Hb, HCT, and serum ferritin than the control group, however there was no significant relationship between ferritin levels and the severity of TE.

Elethawi and Jabbar found that individuals with chronic TE had significantly lower blood ferritin levels (17.6ng/ml) compared to control group (41.2ng/ml). However, Hb levels did not differ significantly between both groups⁽²¹⁾.

The findings of the present work are consistent with previous studies, which found that TE patients had significantly lower levels of iron parameters such as

serum iron, Hb, and ferritin, as well as significantly higher levels of serum iron binding capacity than controls⁽²²⁻²⁵⁾.

In contrast, several investigators found that ferritin and Hb levels in TE patients were not substantially different from those of control persons⁽²⁶⁻²⁸⁾. Furthermore, Bregy and Trueb discovered no link between ferritin levels and telogen ratios⁽²⁹⁾.

Sinclair found that 12 patients with TE having serum ferritin less than 20µg/l received iron supplementation for 3 months; four patients still had low ferritin levels and required further iron administration for another 3 months. Despite the increased serum ferritin in all patients, the therapy did not improve hair shedding or density. Accordingly, they recommended that low iron levels did not promote hair loss⁽³⁰⁾.

We think variation in ferritin and Hb levels between trials can be ascribed to a variety of factors. The findings may differ depending on social lifestyle practices such as insufficient iron intake and poor iron absorption due to excessive tea drinking. Although ferritin is a reliable indicator of iron deficiency, it may be unreliable in cases of chronic inflammation and infection.

The current research discovered a significant difference in H. pylori Ag results between the studied subjects (positive in 60% of cases, 20% of controls). Furthermore, patients with positive H. pylori Ag had significantly lower serum ferritin, Hb, and HCT levels than those with negative H. pylori Ag.

H. pylori infection may be linked to anaemia by reducing iron absorption due to chronic gastritis, which induces stomach hypochlorhydria, resulting in an impaired conversion of dietary iron from ferric to ferrous form⁽³¹⁾.

Other researchers reported low levels of ferritin in 14.5% and 8.6% of H. pylori positive and negative subjects, respectively⁽³²⁻³⁴⁾, which is consistent with our findings.

It was found that H. pylori eradication treatment with iron supplementation is more effective than iron administration alone in the management of iron deficiency anaemia (IDA)⁽³⁵⁾.

Several meta-analyses confirmed a substantial relationship between H. pylori infection and IDA⁽³⁶⁾. IDA during H. pylori infection is primarily caused by gastric bleeding, diminished iron absorption, and the increase in hepcidin levels⁽³⁷⁾.

Our findings contradict other finding of considerably higher blood ferritin levels in H. pylori infection⁽³⁸⁾. The disparity could be explained by differences in sample sizes, participant ages, and associations.

In addition, the link between H. pylori infection and iron in children with upper gastrointestinal symptoms was investigated. They found no significant difference between negative and positive H. pylori status-related ferritin and Hb levels⁽³⁹⁾.

Conclusion

The current study suggests H. pylori testing in TE patients, mainly those with iron deficiency.

References

1. Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. *Cureus*. 2020;12:e8320.
2. Grover C, Khurana A. Telogen effluvium. *Indian J Dermatol Venereol Leprol*. 2013;79:591.
3. Shrivastava SB. Diffuse hair loss in an adult female: approach to diagnosis and management. *Indian J Dermatol Venereol Leprol*. 2009;75:20.
4. Chartier MB, Hoss DM, Grant-Kels JM. Approach to the adult female patient with diffuse nonscarring alopecia. *J Am Acad Dermatol*. 2002;47:809-18.
5. Aziz AMA, Hamed SS, Gaballah MA. Possible relationship between chronic telogen effluvium and changes in lead, cadmium, zinc, and iron total blood levels in females: A case-control study. *Int J Trichology*. 2015;7:100.
6. Rushton DH. Nutritional factors and hair loss. *Clin Exp Dermatol*. 2002;27:396-404.
7. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair

- loss: a review. *Dermatol Ther (Heidelb)*. 2019;9:51-70.
8. Rushton DH, Barth JH. What is the evidence for gender differences in ferritin and haemoglobin? *Crit Rev Oncol Hematol*. 2010;73:1-9.
 9. El-Faragy SM, Yasien HAE-H, Montaser BAE-M, Rashad H. Screening of *Helicobacter pylori* in alopecia areata patients. *Menoufia Med J*. 2017;30:935.
 10. Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, et al. *Helicobacter pylori* associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. *World J Gastroenterol*. 2014;20:5461.
 11. Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. *Helicobacters* and extragastric diseases. *Helicobacter*. 2009;14:58-68.
 12. Mendoza E, Duque X, Hernández Franco JJ, Reyes Maldonado E, Morán S, Martínez G, et al. Association between active *H. pylori* infection and iron deficiency assessed by serum hepcidin levels in school-age children. *Nutrients*. 2019;11:2141.
 13. Piérard GE, Piérard-Franchimont C, Marks R, Elsner P. EEMCO guidance for the assessment of hair shedding and alopecia. *Skin Pharmacol Physiol*. 2004;17:98-110.
 14. Chien Yin GO, Siong-See JL, Wang ECE. Telogen Effluvium—a review of the science and current obstacles. *J Dermatol Sci*. 2021;101(3):156-163.
 15. Sant'Anna Addor FA, Donato LC, Melo CSA. Comparative evaluation between two nutritional supplements in the improvement of telogen effluvium. *Clin Cosmet Investig Dermatol*. 2018;431-6.
 16. Ertug EY, Yilmaz RA. Research Article Reduced ferritin, folate, and vitamin B12 levels in female patients diagnosed with telogen effluvium. *Int J Med Biochem*. 2018;1:111-4.
 17. Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. *Clinical chemistry*. 1998;44:45-51.
 18. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. *J Invest Dermatol*. 2003;121:985-8.
 19. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. *J Am Acad Dermatol*. 2006;54:824-44.
 20. Miniaci MC, Irace C, Capuozzo A, Piccolo M, Di Pascale A, Russo A, et al. Cysteine prevents the reduction in keratin synthesis induced by iron deficiency in human keratinocytes. *J Cell Biochem*. 2016;117:402-12.
 21. Elethawi AMD, Jabbar RI. Comparison between hemoglobin serum level and serum ferritin level in detecting low iron store in adult menstruating females with chronic telogen effluvium. *Iraqi Postgrad Med J*. 2012;11:87-91.
 22. Fatani M, Mahdi A, Alafif K, Hussain W, Khan A, Banjar A. Prevalence and factors associated with telogen effluvium in adult females at Makkah region, Saudi Arabia: a retrospective study. *Journal of Dermatology & Dermatologic Surgery*. 2015;19:27-30.
 23. Karadağ AS, Ertugrul DT, Tural E, Akin KO. The role of anemia and vitamin D levels in acute and chronic telogen effluvium. *Turk J Med Sci*. 2011;41:827-33.
 24. Ozuguz P, Dogruk Kacar S, Ekiz O. Evaluation of zinc, vitamin B12, folic acid and iron levels and thyroid functions in patients with chronic telogen effluvium. *J Dermatol Res Ther*. 2015;1:008.
 25. Ullah I, Paracha MM, Khan ZU, Shahzad A, Zahoor H, Khan M, et al. The relationship of serum ferritin levels, in female patients with Telogen Effluvium: A case control study. *J Med Sci*. 2019;27:116-9.
 26. Olsen EA, Reed KB, Cacchio PB, Caudill L. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. *J Am Acad Dermatol*. 2010;63:991-9.
 27. Alizadeh N, Rafiei R, Darjani A, Eftekhari H, Nejad KG, Rafiei E, et al. Chronic telogen effluvium in women: role of micronutrients, a case-control study in north of Iran. *J. Egypt. Women's Dermatol. Soc*. 2021;18:205-9.
 28. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. *J Invest Dermatol*. 2003;121:985-8.
 29. Bregy A, Trueb RM. No association between serum ferritin levels >10 microg/l and hair loss activity in women. *Dermatology*. 2008;217:1-6.
 30. Sinclair R. There is no clear association between low serum ferritin and chronic diffuse telogen hair loss. *Br J Dermatol*. 2002;147(5):982-4.
 31. Campuzano-maya G. *Helicobacter pylori* and Hematologic Diseases. *World J Gastroenterol*. 2016;33-9.
 32. Muhsen K, Barak M, Shifnaidel L, Nir A, Bassal R, Cohen D. *Helicobacter pylori* infection is associated with low serum ferritin levels in Israeli Arab Children—a seroepidemiologic study. *J Pediatr Gastroenterol Nutr*. 2009;49:262-4.
 33. Qujeq D, Sadogh M, Savadkahi S. Association between *Helicobacter pylori* infection and

- serum iron profile. *Caspian J Intern Med*. 2011;2:266.
34. Queiroz DMM, Harris PR, Sanderson IR, Windle HJ, Walker MM, Rocha AMC, et al. Iron status and *Helicobacter pylori* infection in symptomatic children: an international multi-centered study. *PLoS One*. 2013;8:e68833.
35. Huang X, Qu X, Yan W, Huang Y, Cai M, Hu B, et al. Iron deficiency anaemia can be improved after eradication of *Helicobacter pylori*. *Postgrad Med J*. 2010;86:272-8.
36. Hudak L, Jaraisy A, Haj S, Muhsen K. An updated systematic review and meta-analysis on the association between *Helicobacter pylori* infection and iron deficiency anemia. *Helicobacter*. 2017;22:1-16.
37. Mendoza E, Duque X, Hernández Franco JI, Reyes Maldonado E, Morán S, Martínez G, et al. Association between Active *H. pylori* Infection and Iron Deficiency Assessed by Serum Hcpidin Levels in School-Age Children. *Nutrients*. 2019;11:2141.
38. Kishore G, Ejaz M, Kumar J, Lal A, Tahir H, Anjum Z, et al. Association between *Helicobacter pylori* infection and serum iron profile. *Cureus*. 2021;13.
39. Janjetic MA, Goldman CG, Balcarce NE, Rua EC, González AB, Fuda JA, et al. Iron, zinc, and copper nutritional status in children infected with *Helicobacter pylori*. *J Pediatr Gastroenterol Nutr*. 2010;51:85-9.

To cite this article: Sherine H. Abd El Rahman, Eman A. El hady, Karem T. Khalil. Screening of *Helicobacter Pylori* Infection in Patients with Telogen Effluvium. *BMFJ* 2024;41(8):481-488.